Chimin(SH:603222) Ge Long Hui·2025-09-29 08:24Core Viewpoint - Jimin Health (603222.SH) announced that its subsidiary, Hainan Jimin Boao International Hospital, received a clinical trial acceptance notice from the National Medical Products Administration (NMPA) for the DB006 oncolytic adenovirus injection, aimed at treating advanced malignant solid tumors [1] Group 1: Company Developments - The Boao International Hospital's DB006 oncolytic adenovirus injection is a gene therapy drug designed for advanced malignant solid tumors [1] - The product utilizes genetic engineering to modify oncolytic viruses for selective infection of tumor cells and enhanced tumor-specific replication capabilities [1] - The drug incorporates multiple anti-tumor and immune-regulating genes to target and kill tumors through various mechanisms [1]